The study and its comparison
Researchers assigned 156 people with newly diagnosed type 2 diabetes or prediabetes to metformin alone or metformin plus Bifidobacterium animalis subsp. lactis BB-12. Gastrointestinal symptoms were tracked early and metabolic measurements at three months. [1]
The combination group had higher treatment adherence, fewer reported gastrointestinal symptoms and a greater HbA1c reduction. The findings did not establish comparable improvements in weight or blood lipids. [1]
What the finding establishes
The comparator did not include matching probiotic placebo, and improved adherence could contribute to glucose differences. The preparation-specific result is not proof for every probiotic. Funding and conflicts were not established from the abstract. Medication changes belong with the prescriber. [1]
A hypothetical distinction
Imagine better tolerance leads people to take more of their prescribed medicine. A glucose change cannot automatically be assigned to a separate direct probiotic effect.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Metformin with Versus without Concomitant Probiotic Therapy in Newly Diagnosed Patients with Type 2 Diabetes or Prediabetes: A Comparative Analysis in Relation to Glycemic Control, Gastrointestinal Side Effects, and Treatment Compliance.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.